At LAB+ Company Builder, we believe the future of biotech, life sciences, agtech, and medtech is being written today: by bold scientists transforming deep research into breakthroughs that can reshape humanity’s future. Partnering with these visionary founders is more than investing in companies; it is joining a mission fueled by science, purpose, and a spirit of possibility.
Investors are increasingly drawn to this mission. Our thesis, combining real purpose, rigorous science, and strong return potential, resonates widely. The biotech sector is evolving into a dynamic “tech-bio” frontier, where artificial intelligence and machine learning drive extraordinary efficiencies, from drug discovery to healthcare delivery.
We see this transformation in our portfolio. Guska’s partnership with Marvik, a leading AI firm, shows how biotech and AI can supercharge innovation. B4-RNA has brought in top AI talent, while Locbio and Scaffold Biotech have embedded AI into their platforms, merging computational power with biological insight. The results are not incremental, they are exponential.
Beyond AI, we are entering a new era of convergence. Synthetic Biology and AI, Neuroscience and Robotics, Genome Editing and Data Science, Nanotechnology and Drug Delivery, Immunotherapy and Machine Learning, Quantum Computing and Molecular Simulation—each pairing opens pathways to discoveries once thought impossible. These fusions promise not just better therapies but entirely new industries.
Our portfolio companies are already proving what’s possible. At the recent Richie event in Boston, at conferences all over the world, in partnerships with world-leading academic institutions, LAB+ companies showcase their global innovation. Scaffold Biotech’s GMP vaccine production unit at Institut Pasteur is another striking example of science moving swiftly from lab to world stage.
This is only the beginning. The exponential power of technology demands that we continually expand our mental horizons, test new hypotheses, and pioneer novel approaches. LAB+ companies are not spectators in this transformation, they are front runners. Their work will disrupt industries, unlock new markets, and deliver health and sustainability benefits at global scale.
For us, this is not just an investment journey. It is a mission to accelerate progress toward a healthier, more sustainable, and more vibrant future. At LAB+, we partner with founders to transform today’s breakthroughs into tomorrow’s universal solutions.
